NDAORALTABLET
Approved
Dec 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYSTOLIC (nebivolol hydrochloride) is an oral beta-blocker tablet approved in 2007 for hypertension management. It is a selective beta-1 adrenergic receptor antagonist that reduces blood pressure by decreasing heart rate and contractility. The drug is used in patients requiring cardiovascular risk reduction and blood pressure control.
$24.0MPart D
LOE ApproachingProduct approaching loss of exclusivity with declining market penetration; commercial teams should focus on lifecycle extension and managed transition strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BYSTOLIC offers experience in late-stage brand management and market defense strategies as LOE approaches. Career advancement is contingent on driving retention, managed transition, or identifying label expansion opportunities before generic erosion accelerates.
Brand ManagerMedical Science Liaison
Worked on BYSTOLIC at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.